Webinar Spotlight

Gain critical insights and in-depth knowledge from leading figures in cardiometabolic health at your own pace.

Webinar Spotlight

Christie M. Ballantyne,
MD

Evolving Lipid Management

CMHC co-chair Christie M. Ballantyne, MD, will discuss the topic of CVD prevention in the cardiometabolic patient in light of the recently released cholesterol and comprehensive primary prevention guidelines. Dr. Ballantyne will also discuss the evolution of lipid therapy and lipid targets, including the role of Lp(a) and hypertriglyceridemia in treatment and prevention, as well as lifestyle and obesity management.

Pam Taub
MD, FACC

The Importance of Navigating Female Cardiometabolic Care

Dr Pam Taub will discuss the unique risk factors and challenges faces by women in cardiometabolic health. As Associate Professor of Medicine in the Division of Cardiovascular Medicine at the University of California San Diego, Dr. Taub also serves as Director of the Step Family Foundation Cardiovascular Rehabilitation and Wellness Center, focusing on best practices to actively engage patients and the community in prevention of cardiovascular disease.

Anne L. Peters
MD

The Emerging Role of Technology in Type 2 Diabetes Management

CMHC faculty and diabetes expert Dr. Anne L. Peters discusses why we need to look beyond HbA1c as a target, particularly for patients with cardiovascular risk, and how technology can help improve outcomes. Dr. Peters also discusses practical steps and strategies to optimize the use of technology, including CGM devices, for diabetes management in everyday practice.

Deepak Bhatt
MD, MPH

REDUCE-IT: Data, Cost-Effectiveness, and Guidelines

CMHC Senior Planning Committee member and renowned physician and researcher Dr. Deepak Bhatt, will overview the recent advances in addressing residual atherosclerotic risk. While hypercholesterolemia is an important, modifiable risk factor of ASCVD, residual risk may be present after optimization of LDL-C levels. Recent results with icosapent ethyl, as demonstrated by the REDUCE-IT trial, have shown that this agent can significantly reduce atherosclerotic events in high-risk hypertriglyceridemic patients with clinical ASCVD or type 2 diabetes and additional markers of increased risk. Dr. Bhatt, one of the principal investigators of the REDUCE-IT trial, will review the results of this trial and its clinical practice implications.

George Bakris,
MD

Cardio-Renal Benefits with GLP-1 RAs and SGLT-2 Inhibitors

CMHC Chairs George Bakris, MD, Professor of Medicine and Director of the ASH Comprehensive Hypertension Center at University of Chicago Medicine and Jay S. Skyler, MD, Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology, Diabetes, & Metabolism at University of Miami Miller School of Medicine, review the recent data about the cardio-renal benefits with GLP-1 RAs and SGLT-2 inhibitors in patients with diabetes, and what they mean to the practicing clinician.